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To the Editor, 
We read the recently published article by Macaluso et al. examining the appearance of 
lupus-like reactions (LLR) in patients with inflammatory bowel disease (IBD), who were 
treated with anti-TNF drugs, with great interest (1). It is well-known, that IBD can be associated 
with extraintestinal manifestations, and that sometimes anti-TNF therapy can also generate 
paradox reactions, such as psoriasiform cutaneous reactions and arthritis (2), however LLR as 
a paradoxical reaction is a relatively new kid on the block. Our aim is to contribute to the 
knowledge of the rare-occuring LLRs with our experience. 
The total of 183 IBD patients received infliximab (IFX) or adalimumab (ADA) between 
2012 and the August of 2019 in our center, totally contributed 1403 person-years follow-up. 
During this interval, 3 patients [1.64%; 2 women, 1 man; mean age at the diagnosis: 35.3 years 
(range: 26-51)] were presented with biological-therapy-induced-LLR according to the criteria 
of Macaluso et al, therefore the incidence rate of LRR was 2.14 per 1000 person-years. Female 
gender represents 66.7% of the LLR patients and 53.3% of the non-LLR group, while smokers 
represent 33.3% of the LLR patients and 12.3% of the non-LLR group. In regard to the low 
number of LLR patients, the value of these data has to be considered. 
Two patients have Crohn’s disease (CD) and one has ulcerative colitis (UC). All patients 
had IFX as the offending drug, which was the first-line biological treatment in two cases, while 
the remaining one patient had previously received ADA. All of them were in clinical remission 
at the time of the LLR diagnosis, but have experienced the most extended forms of IBD before: 
our UC paitent has already had pancolitis and our two CD patients have experienced ileocolic 
localisation with the involvement of the upper gastrointestinal tract as well. Arthralgia was 
reported in all 3 cases, while fatigue occurred in 2 cases, and cutaneous manifestation in 1 
patient. None of the patients developed fever or serositis, but two of them experienced the 
symptoms of myositis showing muscular involvement, which was also confirmed by the 
elevated level of the muscle-specific Jo-1 autoimmune antibody in one case. Both ANA and 
anti-ds-DNA titers were elevated in 2-2 patients, respectively. Furthermore, other less common 
lupus-antibody titers also showed elevation: rheumatoid factor (2 patients), antiribosomal P-
protein antibody (1 patient), anti-nucleosome antibody (1 patient), and the drug-induced 
autoimmunity marker histone antibody (1 patient) were found. We have drug monitoring data 
from two patients. Both were presented with subtherapeutic IFX levels (2.75ng/l and 0.12ng/l) 
and anti-drug antibody positivity. Six months after the LLR diagnosis and consequent drug 
disposal, the control autoimmune titers remained higher than normal in all cases. All three 
patients received combination therapy with azathioprine. None of them received steroids when 
the diagnosis of LLR was set up, but all of them had LRR just after steroid withdrawal.  
Our results can confirm the observation of Macalusco et al that LLR can exist more 
frequently among women and former smokers, however we hypothesize the role of drug 
antibody formation and steroid withdrawal in the development of LLR. Serum drug level 
measurement and an autoimmune panel should be performed after a one-year therapy, and in 
case of subtherapeutic drug level and elevated antibodies, a biological drug switch should be 
considered.  
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